Published in Inflammopharmacology on February 25, 2015
A novel pH-controlled hydrogen sulfide donor protects gastric mucosa from aspirin-induced injury. J Cell Mol Med (2017) 0.75
Dysphagia after vertical sleeve gastrectomy: Evaluation of risk factors and assessment of endoscopic intervention. World J Gastroenterol (2016) 0.75
Proton pump inhibitor use may not prevent high-grade dysplasia and oesophageal adenocarcinoma in Barrett's oesophagus: a nationwide study of 9883 patients. Aliment Pharmacol Ther (2014) 3.37
Hydrogen sulfide is an endogenous modulator of leukocyte-mediated inflammation. FASEB J (2006) 3.37
Medications (NSAIDs, statins, proton pump inhibitors) and the risk of esophageal adenocarcinoma in patients with Barrett's esophagus. Gastroenterology (2010) 1.51
Pill-induced esophageal injury: endoscopic features and clinical outcomes. Endoscopy (2005) 1.36
Markedly reduced toxicity of a hydrogen sulphide-releasing derivative of naproxen (ATB-346). Br J Pharmacol (2010) 1.34
Nonsteroidal anti-inflammatory drugs and the esophageal inflammation-metaplasia-adenocarcinoma sequence. Cancer Res (2006) 1.32
Doxycycline-induced pill esophagitis. Dis Esophagus (2004) 1.31
Diagnosis and management of non-erosive reflux disease--the Vevey NERD Consensus Group. Digestion (2009) 1.19
Aspirin, nonsteroidal anti-inflammatory drugs, and the risks of cancers of the esophagus. Cancer Epidemiol Biomarkers Prev (2008) 1.10
Gastro-oesophageal reflux symptoms and the risks of oesophageal cancer: are the effects modified by smoking, NSAIDs or acid suppressants? Gut (2010) 1.04
Anti-inflammatory and cytoprotective actions of hydrogen sulfide: translation to therapeutics. Antioxid Redox Signal (2014) 1.02
Preventive effect of irsogladine or omeprazole on non-steroidal anti-inflammatory drug-induced esophagitis, peptic ulcers, and small intestinal lesions in humans, a prospective randomized controlled study. BMC Gastroenterol (2013) 0.97
Gastrointestinal-sparing effects of novel NSAIDs in rats with compromised mucosal defence. PLoS One (2012) 0.93
Hydrogen sulfide-based therapeutics and gastrointestinal diseases: translating physiology to treatments. Am J Physiol Gastrointest Liver Physiol (2013) 0.92
NSAID-gastroenteropathy: new aspects of pathogenesis and prevention. Curr Opin Pharmacol (2014) 0.92
Gastroesophageal reflux disease--from reflux episodes to mucosal inflammation. Nat Rev Gastroenterol Hepatol (2011) 0.91
Risk factors of oesophagitis in arthritic patients. Eur J Gastroenterol Hepatol (2001) 0.90
STUDIES ON THE DRUGS FOR PEPTIC ULCER. A RELIABLE METHOD FOR PRODUCING STRESS ULCER IN RATS. Chem Pharm Bull (Tokyo) (1964) 0.88
Nonsteroidal anti-inflammatory drugs, proton pump inhibitors, and gastrointestinal injury: contrasting interactions in the stomach and small intestine. Mayo Clin Proc (2014) 0.88
Cyclooxygenase-2 (COX-2) is the key event in pathophysiology of Barrett's esophagus. Lesson from experimental animal model and human subjects. J Physiol Pharmacol (2010) 0.86
Association of esophagitis and esophageal strictures with diseases treated with nonsteroidal anti-inflammatory drugs. Am J Gastroenterol (1997) 0.85
Drug-induced injury in the gastrointestinal tract. Semin Diagn Pathol (2014) 0.83
Animal model of acid-reflux esophagitis: pathogenic roles of acid/pepsin, prostaglandins, and amino acids. Biomed Res Int (2014) 0.78
Nonsteroidal anti-inflammatory drugs and the risk of Barrett's esophagus. Clin Gastroenterol Hepatol (2014) 0.77
Pill-induced esophagitis. Gastroenterol Hepatol (N Y) (2007) 0.77
Interdisciplinary review for correlation between the plant origin capsaicinoids, non-steroidal antiinflammatory drugs, gastrointestinal mucosal damage and prevention in animals and human beings. Inflammopharmacology (2009) 0.77
Aspirin and nonsteroidal anti-inflammatory drug use and the risk of Barrett's esophagus. Dig Dis Sci (2014) 0.77
Cytoprotective effects of hydrogen sulfide in novel rat models of non-erosive esophagitis. PLoS One (2014) 0.77
Effects of nitrosative stress and reactive oxygen-scavenging systems in esophageal physiopathy under streptozotocin-induced experimental hyperglycemia. J Physiol Pharmacol (2008) 0.76
Naproxen induced ulcerative esophagitis. J Rheumatol (1992) 0.76
Molecular mechanisms of acid exposure in Barrett's esophagus. Inflammopharmacology (2007) 0.76
Message in a bottle: decoding medication injury patterns in the gastrointestinal tract. J Clin Pathol (2014) 0.76
Esophageal COX-2 expression is increased in Barrett's esophagus, obesity, and smoking. Dig Dis Sci (2014) 0.75
Pill -Induced Erosive Esophagitis in Children. Clujul Med (2014) 0.75
Non-reflux esophagitis: a review of inflammatory diseases of the esophagus exclusive of reflux esophagitis. Semin Diagn Pathol (2014) 0.75
New insight into oseophageal injury and protection in physiologically relevant animal models. J Physiol Pharmacol (2014) 0.75
Pill Esophagitis. Curr Treat Options Gastroenterol (2004) 0.75
Resolution of inflammation: state of the art, definitions and terms. FASEB J (2007) 5.12
Matrix metalloproteinase processing of monocyte chemoattractant proteins generates CC chemokine receptor antagonists with anti-inflammatory properties in vivo. Blood (2002) 3.58
Hydrogen sulfide is an endogenous modulator of leukocyte-mediated inflammation. FASEB J (2006) 3.37
Human endogenous retrovirus glycoprotein-mediated induction of redox reactants causes oligodendrocyte death and demyelination. Nat Neurosci (2004) 2.64
Inhibition of hydrogen sulfide generation contributes to gastric injury caused by anti-inflammatory nonsteroidal drugs. Gastroenterology (2005) 2.58
Induction of intestinal inflammation in mouse by activation of proteinase-activated receptor-2. Am J Pathol (2002) 2.16
Concern A beta-oxidation-resistant lipoxin A4 analog treats hapten-induced colitis by attenuating inflammation and immune dysfunction. Proc Natl Acad Sci U S A (2004) 2.13
The emerging roles of hydrogen sulfide in the gastrointestinal tract and liver. Gastroenterology (2006) 2.08
Microglial activation and beta -amyloid deposit reduction caused by a nitric oxide-releasing nonsteroidal anti-inflammatory drug in amyloid precursor protein plus presenilin-1 transgenic mice. J Neurosci (2002) 2.03
Proteinase-activated receptors 1 and 4 counter-regulate endostatin and VEGF release from human platelets. Proc Natl Acad Sci U S A (2004) 1.76
Synthesis and biological effects of hydrogen sulfide (H2S): development of H2S-releasing drugs as pharmaceuticals. J Med Chem (2010) 1.63
Evidence that hydrogen sulfide exerts antinociceptive effects in the gastrointestinal tract by activating KATP channels. J Pharmacol Exp Ther (2005) 1.56
A major role for proteolytic activity and proteinase-activated receptor-2 in the pathogenesis of infectious colitis. Proc Natl Acad Sci U S A (2005) 1.45
Cyclooxygenase-2-derived lipoxin A4 increases gastric resistance to aspirin-induced damage. Gastroenterology (2002) 1.33
Proteinase-activated receptor 1 activation induces epithelial apoptosis and increases intestinal permeability. Proc Natl Acad Sci U S A (2003) 1.32
Colitis induced by proteinase-activated receptor-2 agonists is mediated by a neurogenic mechanism. Can J Physiol Pharmacol (2003) 1.17
Retracted A role for proteinase-activated receptor-1 in inflammatory bowel diseases. J Clin Invest (2004) 1.15
Divergent effects of new cyclooxygenase inhibitors on gastric ulcer healing: Shifting the angiogenic balance. Proc Natl Acad Sci U S A (2002) 1.13
Interaction of a selective cyclooxygenase-2 inhibitor with aspirin and NO-releasing aspirin in the human gastric mucosa. Proc Natl Acad Sci U S A (2003) 1.11
Relative contribution of acetylated cyclo-oxygenase (COX)-2 and 5-lipooxygenase (LOX) in regulating gastric mucosal integrity and adaptation to aspirin. FASEB J (2003) 1.09
Gastrointestinal inflammation: a central component of mucosal defense and repair. Exp Biol Med (Maywood) (2006) 1.06
Hydrogen sulphide synthesis in the rat and mouse gastrointestinal tract. Dig Liver Dis (2009) 1.06
Annexin-1 modulates repair of gastric mucosal injury. Am J Physiol Gastrointest Liver Physiol (2008) 1.03
A pro-resolution mediator, prostaglandin D(2), is specifically up-regulated in individuals in long-term remission from ulcerative colitis. Proc Natl Acad Sci U S A (2010) 1.01
Retracted A NO-releasing derivative of acetaminophen spares the liver by acting at several checkpoints in the Fas pathway. Br J Pharmacol (2002) 1.01
5-Amino-2-hydroxybenzoic acid 4-(5-thioxo-5H-[1,2]dithiol-3yl)-phenyl ester (ATB-429), a hydrogen sulfide-releasing derivative of mesalamine, exerts antinociceptive effects in a model of postinflammatory hypersensitivity. J Pharmacol Exp Ther (2006) 1.00
Proteinase-activated receptor (PAR)-1 and -2 agonists induce mediator release from mast cells by pathways distinct from PAR-1 and PAR-2. J Pharmacol Exp Ther (2002) 0.99
Sildenafil prevents indomethacin-induced gastropathy in rats: role of leukocyte adherence and gastric blood flow. Br J Pharmacol (2005) 0.98
Up-regulation of Annexin-A1 and lipoxin A(4) in individuals with ulcerative colitis may promote mucosal homeostasis. PLoS One (2012) 0.98
Hydrogen sulfide: a rescue molecule for mucosal defence and repair. Dig Dis Sci (2012) 0.97
Letter by Wallace and Chan regarding article, "Drug resistance and pseudoresistance: an unintended consequence of enteric coating aspirin". Circulation (2013) 0.96
Eukaryotic and prokaryotic contributions to colonic hydrogen sulfide synthesis. Am J Physiol Gastrointest Liver Physiol (2011) 0.95
Gastritis increases resistance to aspirin-induced mucosal injury via COX-2-mediated lipoxin synthesis. Am J Physiol Gastrointest Liver Physiol (2003) 0.94
Effects of chondroitin and glucosamine sulfate in a dietary bar formulation on inflammation, interleukin-1beta, matrix metalloprotease-9, and cartilage damage in arthritis. Exp Biol Med (Maywood) (2005) 0.94
Mechanisms of nonsteroidal anti-inflammatory drug-induced gastrointestinal injury and repair: a window of opportunity for cyclooxygenase-inhibiting nitric oxide donors. Can J Gastroenterol (2004) 0.94
Efficacy and age-related effects of nitric oxide-releasing aspirin on experimental restenosis. Proc Natl Acad Sci U S A (2002) 0.93
Gastrointestinal-sparing effects of novel NSAIDs in rats with compromised mucosal defence. PLoS One (2012) 0.93
Nitric oxide and inflammation. Inflamm Allergy Drug Targets (2006) 0.93
Cooperation between aspirin-triggered lipoxin and nitric oxide (NO) mediates antiadhesive properties of 2-(Acetyloxy)benzoic acid 3-(nitrooxymethyl)phenyl ester (NCX-4016) (NO-aspirin) on neutrophil-endothelial cell adherence. J Pharmacol Exp Ther (2004) 0.93
Inhibition of cyclo-oxygenase-2 exacerbates ischaemia-induced acute myocardial dysfunction in the rabbit. Br J Pharmacol (2002) 0.92
Hydrogen sulfide-based therapeutics and gastrointestinal diseases: translating physiology to treatments. Am J Physiol Gastrointest Liver Physiol (2013) 0.92
Aspirin-triggered, cyclooxygenase-2-dependent lipoxin synthesis modulates vascular tone. Circulation (2004) 0.91
A vascular endothelial growth factor mimetic accelerates gastric ulcer healing in an iNOS-dependent manner. Am J Physiol Gastrointest Liver Physiol (2008) 0.90
Protease-activated receptor-2 activation improves efficiency of experimental ischemic preconditioning. Am J Physiol Heart Circ Physiol (2002) 0.90
Hydrogen sulfide and resolution of acute inflammation: A comparative study utilizing a novel fluorescent probe. Sci Rep (2012) 0.89
Interactions of hydrogen sulfide with myeloperoxidase. Br J Pharmacol (2014) 0.89
Enhanced synthesis and diminished degradation of hydrogen sulfide in experimental colitis: a site-specific, pro-resolution mechanism. PLoS One (2013) 0.88
Evidence that 5-lipoxygenase and acetylated cyclooxygenase 2-derived eicosanoids regulate leukocyte-endothelial adherence in response to aspirin. Br J Pharmacol (2003) 0.88
Predisposition to colorectal cancer in rats with resolved colitis: role of cyclooxygenase-2-derived prostaglandin d2. Am J Pathol (2005) 0.87
A hydrogen sulfide-releasing cyclooxygenase inhibitor markedly accelerates recovery from experimental spinal cord injury. FASEB J (2013) 0.87
Roles of platelets and proteinase-activated receptors in gastric ulcer healing. Dig Dis Sci (2005) 0.85
Hydrogen sulfide inhibits oxidative stress in lungs from allergic mice in vivo. Eur J Pharmacol (2012) 0.84
Citrobacter rodentium infection causes iNOS-independent intestinal epithelial dysfunction in mice. Can J Physiol Pharmacol (2006) 0.83
Nitric oxide synthase and nitric oxide production in in vivo-derived mast cells. J Leukoc Biol (2002) 0.83
Hydrogen sulfide protects from colitis and restores intestinal microbiota biofilm and mucus production. Inflamm Bowel Dis (2015) 0.83
A protease activated receptor-2 (PAR-2) activating peptide, tc-LIGRLO-NH2, induces protease release from mast cells: role in TNF degradation. BMC Pharmacol (2004) 0.82
Environmental and NSAID-enteropathy: dysbiosis as a common factor. Curr Gastroenterol Rep (2014) 0.82
Mucosal repair and COX-2 inhibition. Curr Pharm Des (2003) 0.82
Deciphering the pathogenesis of NSAID enteropathy using proton pump inhibitors and a hydrogen sulfide-releasing NSAID. Am J Physiol Gastrointest Liver Physiol (2015) 0.81
A comparative study on the anti-inflammatory effects of single oral doses of naproxen and its hydrogen sulfide (H2S)-releasing derivative ATB-346 in rats with carrageenan-induced synovitis. Med Gas Res (2013) 0.80
Enhanced anti-inflammatory potency of a nitric oxide-releasing prednisolone derivative in the rat. Br J Pharmacol (2003) 0.80
A role for proteinase-activated receptor-1 in inflammatory bowel diseases. J Clin Invest (2006) 0.80
Annexin-1 is an endogenous gastroprotective factor against indomethacin-induced damage. Am J Physiol Gastrointest Liver Physiol (2004) 0.79
Roles of platelet and endothelial cell COX-1 in hypercholesterolemia-induced microvascular dysfunction. Am J Physiol Heart Circ Physiol (2007) 0.79
COX-inhibiting nitric oxide donors (CINODs): potential benefits on cardiovascular and renal function. Cardiovasc Hematol Agents Med Chem (2006) 0.79
Hydrogen sulphide protects against NSAID-enteropathy through modulation of bile and the microbiota. Br J Pharmacol (2014) 0.78
Acetic acid induced ulceration in rats is not affected by infection with Hymenolepis diminuta. J Parasitol (2009) 0.78
NSAID enteropathy and bacteria: a complicated relationship. J Gastroenterol (2015) 0.78
Anti-inflammatory effects of nitric oxide-releasing hydrocortisone NCX 1022, in a murine model of contact dermatitis. Br J Pharmacol (2004) 0.78
Role of cyclooxygenases in oedema-forming activity of bothropic venoms. Toxicon (2006) 0.76
Effects of conventional and hydrogen sulfide-releasing non-steroidal anti-inflammatory drugs in rats with stress-induced and epinephrine-induced gastric damage. Stress (2014) 0.76
Bothrops jararaca and Crotalus durissus terrificus venoms elicit distinct responses regarding to production of prostaglandins E2 and D2, and expression of cyclooxygenases. Toxicon (2006) 0.76
Effect of CCl4 and blocking H2S biosynthesis on oesophageal mucosa rats: model of nonerosive oesophagitis. Folia Med Cracov (2014) 0.75
A unique therapeutic approach to emesis and itch with a proanthocyanidin-rich genonutrient. J Transl Med (2008) 0.75
Should the CAG advocate for resources with government and governmental agencies? Can J Gastroenterol (2003) 0.75